Title :

Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group

Author(s) :

Meyer, Emmanuel [Auteur]
CHU Caen
Pasquier, David [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 [CRIStAL]
Bernadou, Guillemette [Auteur]
Centre Hospitalier Régional Universitaire de Tours [CHRU Tours]
Calais, Gilles [Auteur]
Clinique d'Oncologie et de Radiothérapie [Tours] [CORAD]
Maroun, Pierre [Auteur]
Institut Gustave Roussy [IGR]
Bossi, Alberto [Auteur]
Département de radiothérapie [Gustave Roussy]
Théodore, Christine [Auteur]
Hôpital Foch [Suresnes]
Albiges, Laurence [Auteur]
Oncologie génito-urinaire
Stefan, Dinu [Auteur]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
de Crevoisier, Renaud [Auteur]
CRLCC Eugène Marquis [CRLCC]
Hennequin, Christophe [Auteur]
CHU Saint-Antoine [AP-HP]
Lagrange, Jean-Léon [Auteur]
Hôpital Henri Mondor
Grellard, Jean-Michel [Auteur]
Centre de recherche clinique [CHU Caen] [CRC]
Clarisse, Bénédicte [Auteur]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Licaj, Idlir [Auteur]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Habrand, Jean-Louis [Auteur]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]
Carrie, Christian [Auteur]
Centre Léon Bérard [Lyon]
Joly, Florence [Auteur]
Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC]

Journal title :

European Journal of Cancer

Pages :

38-47

Publisher :

Elsevier

Publication date :

2018-07

ISSN :

0959-8049

English keyword(s) :

Oligoprogressive disease
Renal cell carcinoma
Stereotactic radiation therapy
Oligometastatic disease

HAL domain(s) :

Sciences du Vivant [q-bio]
Sciences du Vivant [q-bio]/Cancer

English abstract : [en]

BackgroundRenal cell carcinoma (RCC) is usually considered radioresistant, but stereotactic radiation therapy (SRT) may increase local disease control. This study aimed to assess the benefit of SRT in the management of ...
Show more >BackgroundRenal cell carcinoma (RCC) is usually considered radioresistant, but stereotactic radiation therapy (SRT) may increase local disease control. This study aimed to assess the benefit of SRT in the management of metastatic RCC patients.MethodsData of all RCC patients who received SRT between 2008 and 2015 with curative intent were retrospectively collected in six French referral centres. Local control (LC), progression-free survival (PFS), local recurrence-free survival (LRFS), time to systemic therapy (TTS) and overall survival (OS) were assessed.ResultsOne hundred and eighty-eight patients treated with SRT for 252 RCC metastases (brain [n = 120]; spine [n = 75]; and others [n = 57]) were recensed. SRT was performed for oligoprogressive disease (101 patients), oligometastatic disease (80 patients) or residual tumour after a partial response to systemic treatment (7 patients). The median biologically effective dose was 78 Gy. For the whole population, local control rates at 6, 12 and 24 months were 87.5%, 82.9% and 77.6%, respectively; median PFS, LRFS, TTS and OS were 8.5, 23.2, 13.2 and 29.2 months, respectively. Among patients treated for oligoprogressive/oligometastatic disease, the median PFS, TTS, and OS were 8.6/7.6, 10.5/14.2 and 23.2/33.9 months, respectively. Among the 7 patients treated with SRT after partial response to systemic treatment, no relapse occurred for 3 of them after a median follow-up of 22 months. Acute and late severe toxicities were noted in 5 (2.6%) patients.ConclusionsSRT is effective and safe for oligometastatic and oligoprogressive RCC patients and may delay introduction or change of systemic therapy.Show less >

Language :

Anglais

Popular science :

Non

Collections :

• Centre de Recherche en Informatique, Signal et Automatique de Lille (CRIStAL) - UMR 9189

Source :

Harvested from HAL